US ERA ARCHIVE DOCUMENT



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

008271

COMPRESSION

MAR -4 [991

MEMORANDUM

OFFICE OF PESTICIDES AND TOXIC SUBSTANCES

SUBJECT: SACB review of supplemental data/information submitted by Mycogen Corporation to resolve outstanding toxicity/exposure issues related to MYX 7275 (MVP Bioinsecticide). [EPA ID No. 053219-G and 9F03744; Submission Nos. S384201 and S384202; MRID Nos. 416520-01, -02, -03, -04, -05; Caswell No. 714G; HED Project No. 0-2027].

TO:

Willie Nelson/Phil Hutton (PM-17) Insecticide-Rodenticide Branch Registration Division (H7505C)

FROM:

Roy D. Sjoblad, Ph.D., Microbiologist

Science Analysis and Coordination Branch

Health Effects Division (H7509C)

THROUGH:

Reto Engler, Ph.D., Chief

SACB, HED (H7509C)

Background: On 10/16/90, SACB received information from Mycogen, Corp. for the purpose of resolving outstanding SACB issues for an EUP with the chemically-fixed and killed genetically engineered microbial pesticide, MVP. The following information was submitted: Description of technique used to quantify the fixative material, determination of amount of fixative material in the product and use of this datat to estimate dietary exposure, worker exposure data, an intravenous injection study with fixed and chemically fixed bacterial preparations, and a storage stability study. Copies of the proposed label also were submitted. OREB is reviewing the worker exposure data.


SACB Conclusions: The concentration of the description of the analytical method, and estimation of dietary exposure to the analytical method, and estimation of dietary exposure to the serious are adequate to show that under the proposed use there would be no expected concerns for exposure to the fixative material. The intravenous toxicity in rats appeared to be related to a shock response to the test material. The data support the EUP request, under non-crop destruct conditions. The intravenous study is an Acceptable study.

Data/information Submitted:

1. Method used to quantify the level of chemical fixative in the samples, and results of sample analysis.


	2 is not included in this copy.
Pages	
	aterial not included contains the following type of mation:
 	Identity of product inert ingredients.
	Identity of product impurities.
	Description of the product manufacturing process.
	Description of quality control procedures.
 	Identity of the source of product ingredients.
····	Sales or other commercial/financial information.
	A draft product label.
	The product confidential statement of formula.
	Information about a pending registration action.
	FIFRA registration data.
	The document is a duplicate of page(s)
,	The document is not responsive to the request.
by pr	nformation not included is generally considered confidential oduct registrants. If you have any questions, please contact ndividual who prepared the response to your request.

Ξ



3. Storage stability data.

Three batch samples of MVP Bioinsecticide were stored in high-density polyethylene containers at 20°C for up to one-year, and no corrosivity was noticed. Stability of MVP was determined by bioassay with the diamondback moth done at 3, 6, 9, and 12 months after study initiation. There was no significant loss in bioactivity of MVP after 1 year storage under the above conditions. Initial activity was recorded at about 14,000 to 16,000 IU/mg, and final activity was determined to be about 13,000 IU/mg.



Brailles Thuringienses A.I. 6409
Page $4-5$ is not included in this copy.
Pages through are not included in this copy.
The material not included contains the following type of information:
Identity of product inert ingredients.
Identity of product impurities.
Description of the product manufacturing process.
Description of quality control procedures.
Identity of the source of product ingredients.
Sales or other commercial/financial information.
A draft product label.
The product confidential statement of formula.
Information about a pending registration action.
FIFRA registration data.
The document is a duplicate of page(s)
The document is not responsive to the request.
The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.

2

Ä

g) Label Statements.

SACB would recommend that appropriate respiratory tract coverings (in this case a particle dust mask would be appropriate) should be worn by applicators/other exposed workers during application of aerosols of the bioinsecticide. SACB believes that it is prudent to minimize exposure of the respiratory tract to aerosols containing Gram-negative bacterial cell wall components. The label also states that repeat applications of the bioinsecticide are to be done as necessary, and thus there may be repeated exposure to the bacterial cell wall components. The label should be amended to reflect the potential for pulmonary exposure, and wearing of appropriate protective clothing.

Paqe	η is not included in this copy.
Pages	
	aterial not included contains the following type of mation:
	Identity of product inert ingredients.
	Identity of product impurities.
	Description of the product manufacturing process.
	Description of quality control procedures.
	Identity of the source of product ingredients.
ii	Sales or other commercial/financial information.
,	A draft product label.
	The product confidential statement of formula.
	Information about a pending registration action.
	FIFRA registration data.
	The document is a duplicate of page(s)
	The document is not responsive to the request.
·····	
The i	nformation not included is generally considered confident
by pr	oduct registrants. If you have any questions, please continued individual who prepared the response to your request.